Cargando…
Cardiovascular Safety of SGLT2 Inhibitors Compared to DPP4 Inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World Clinical Data in Korea
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Korean Diabetes Association
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369211/ https://www.ncbi.nlm.nih.gov/pubmed/34352987 http://dx.doi.org/10.4093/dmj.2021.0158 |
| _version_ | 1783739245018480640 |
|---|---|
| author | Kim, Kyuho Choi, Sung Hee |
| author_facet | Kim, Kyuho Choi, Sung Hee |
| author_sort | Kim, Kyuho |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8369211 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Korean Diabetes Association |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-83692112021-08-26 Cardiovascular Safety of SGLT2 Inhibitors Compared to DPP4 Inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World Clinical Data in Korea Kim, Kyuho Choi, Sung Hee Diabetes Metab J Editorial Korean Diabetes Association 2021-07 2021-07-30 /pmc/articles/PMC8369211/ /pubmed/34352987 http://dx.doi.org/10.4093/dmj.2021.0158 Text en Copyright © 2021 Korean Diabetes Association https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Editorial Kim, Kyuho Choi, Sung Hee Cardiovascular Safety of SGLT2 Inhibitors Compared to DPP4 Inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World Clinical Data in Korea |
| title | Cardiovascular Safety of SGLT2 Inhibitors Compared to DPP4 Inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World Clinical Data in Korea |
| title_full | Cardiovascular Safety of SGLT2 Inhibitors Compared to DPP4 Inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World Clinical Data in Korea |
| title_fullStr | Cardiovascular Safety of SGLT2 Inhibitors Compared to DPP4 Inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World Clinical Data in Korea |
| title_full_unstemmed | Cardiovascular Safety of SGLT2 Inhibitors Compared to DPP4 Inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World Clinical Data in Korea |
| title_short | Cardiovascular Safety of SGLT2 Inhibitors Compared to DPP4 Inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World Clinical Data in Korea |
| title_sort | cardiovascular safety of sglt2 inhibitors compared to dpp4 inhibitors and sulfonylureas as the second-line of therapy in t2dm using large, real-world clinical data in korea |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369211/ https://www.ncbi.nlm.nih.gov/pubmed/34352987 http://dx.doi.org/10.4093/dmj.2021.0158 |
| work_keys_str_mv | AT kimkyuho cardiovascularsafetyofsglt2inhibitorscomparedtodpp4inhibitorsandsulfonylureasasthesecondlineoftherapyint2dmusinglargerealworldclinicaldatainkorea AT choisunghee cardiovascularsafetyofsglt2inhibitorscomparedtodpp4inhibitorsandsulfonylureasasthesecondlineoftherapyint2dmusinglargerealworldclinicaldatainkorea |